Plné znění - 80/2017 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2017 - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

80/2017 Sb. m. s.

Sdělení

INFORMACE

80

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x č. 46/2008 Xx. m. x.

 

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že xxx 28. listopadu 2016 xxxx generální ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X (Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx rok 2017 - Xxxxxxxxxxx xxxxxxxx) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X novým xxxxxx Xxxxxxx X vyslovil xxxxxxx Parlament Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x přijetí xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. ledna 2017 x xxx Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx dne 30. xxxxx 2017.

Dnem vstupu xxxxxx xxxxx Přílohy X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I xxxxxx xx 1. xxxxx 2016, xxxxxxxxx xxx č. 26/2017 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx do českého xxxxxx xx vyhlašují xxxxxxxx.

XXXXXXX XXXXXXXXXXXXX KODEX

SEZNAM XXXXXXXXXX XXXXX A XXXXX XXXXXXX PRO XXX 2017

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx bude xxxxxxxxx WADA a xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx jakýchkoliv konfliktů xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxx verze.

Tento Xxxxxx bude xxxxxx xx 1. xxxxx 2017 

XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2017

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. ledna 2017

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx metod M1, X2 x M3.

LÁTKY X METODY XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

ZAKÁZANÉ XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv farmakologicky xxxxxx xxxxx, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (např. xxxxxx x preklinickém nebo xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx xxxxxxxx stále.

S1. XXXXXXXXXX LÁTKY

Anabolické látky xxxx xxxxxxxx.

1. ANABOLICKÉ XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* AAS, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion);

bolandiol (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-norpregna-4-en-17α-ol);

fluoxymesteron;

formebolon;

furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestr-4-en-3-on);

methyItestosteron;

metribolon (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Endogenní** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (androst-4-en-3,17-dion);

boldenon;

boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx); 

xxxxxxxxx (19-xxxxxxxxxxxxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x isomery, xxx xx x xxxxxxxx pouze xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (androst-5-en-3,17-dion);

androsteron;

epi-dihydrotestosteron;

epitestosteron;

etiocholanolon;

3ß-hydroxy-5α-androstan-17-on;

7α-hydroxy-DHEA;

7ß-hydroxy-DHEA;

7-keto-DHEA;

19-norandrosteron;

19-noretiocholanolon.

2. Xxxxxxx xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx; selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX, xxxx. xxxxxxx x xxxxxxx); tibolon; xxxxxxx x xxxxxxxxxx, ale xx s omezením xxxxx xx xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "endogenní " xx xxxxxxxx x xxxxx, kterou xxxx normálně přirozeně xxxxxxxxx.

X2. XXXXXXXXX HORMONY, XXXXXXX FAKTORY, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx:

1.1 Xxxxx xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx xxxx.

xxxxxxxxxxxx (xXXX);

xxxxxxxxxxxxx (XXX);

XXX-Xx;

XXX-xxxxxxxxxxx xxxxxxx (XXX), xxxx. CNTO 530 x peginesatid;

inhibitory GATA, xxxx. X-11706;

xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX);

xxxxxxxxxx xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (TGF-beta), xxxx. xxxxxxxxxxx, luspatercept;

1.2 Xxxxxxxx xxxxxxxxxxxxxxxxxx XXX xxxxxxxxx, xxxx.

XXX-290;

xxxxxx XXX;

xxxxxxxxxxxxx XXX;

2. Xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx. xxxxxx, molidustat x roxadustat (FG-4592); x aktivátory HIF, xxxx. xxxxx x xxxxx.

3. Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx hormon (XX) x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx, x xxxx.

4. Xxxxxxxxxxxxxx x jejich xxxxxxxxxx xxxxxxx, např. xxxxxxxxxxxx.

5. Růstový xxxxxx (XX) a xxxx xxxxxxxxxx faktory xxxxxx: xxxxxxx uvolňujícího xxxxxxx xxxxxx (XXXX) x xxxx analogů, xxxx. XXX-1295, xxxxxxxxxxx x xxxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (GHS), xxxx. xxxxxxxx x mimetik xxxxxxxx, např. xxxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxxx, XXXX-6, hexarelinu x xxxxxxxxxxxx (XXXX- 2).

Xxxxx xxxx xxxx xxxxxxxx xxxxxxxxxxx růstové xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx); xxxxxxxxxxxx růstový faktor (XXX); xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1) x xxxx analoga; xxxxxxxxxx xxxxxxx xxxxxxx (XXX); xxxxxxx xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, xxxxx a xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx typy xxxxxxxxx vláken.

S3. XXXX2- XXXXXXXX

Xxxxxxx selektivní x xxxxxxxxxxxx xxxx2- xxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, jsou xxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; olodaterol; xxxxxxxxxx; xxxxxxxxxx; salbutamol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: maximálně 1600 xxxxxxxxxx za 24 xxxxx, xxxxxxxxxxx 800 xxxxxxxxxx xx každých 12 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx dodaná xxxxx 54 xxxxxxxxxx xx 24 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x moči v xxxxxxxxxxx xxxxx než 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou studií, xx xxxxxxxxxx výsledek xxx způsoben užíváním xxxxxxxxxxxx xxxxx (x xxxxxxxx) nižší, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx,

xxx ne x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx; fulvestrant x xxxxxxxx, xxx xx x xxxxxxxx xxxxx na ně.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, ale ne

s xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. AICAR; x Xxxxxxxx Receptoru xxxxx aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. XX 1516;

5.2 Insuliny x xxxxxxxx xxxxxxxx;

5.3 Xxxxxxxxx;

5.4 Trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx xxxx xxxxxxxx, xxxxxx jako další xxxxx x xxxxxxxx xxxxxxxxx strukturou a xxxxxxxxx biologickými xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx, xxxxxxxxxxxxxxx (např. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx xx.

• Xxxxxxxxxxxx, xxxxxxxx, bumetanid, furosemid, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x vaptany (xxxx. xxxxxxxxx), ale xx x xxxxxxxx xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx, xxxxxxxxx x xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx xxxxxxxx limitem (xx. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx kdykoliv xxxx

xxxxxxxx Xxx Soutěži xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxx xxxxxxxxxx Terapeutickou xxxxxxx (TV) xx xxxx xxxxx xxxxx x xx, která xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx znovuzavedení xxxxxxxxxxx xxxxxxxx autologní, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Umělé xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx kyslíku.

Zahrnující:

modifikované xxxxxxxxxxxxx produkty (xxxx. xxxxxx náhražky xxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x xxxxxxxx pouze xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx způsoby.

M2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků odebraných xxx Xxxxxxxxx kontrole. Xx zahrnuje záměnu x/xxxx xxxxxx (např. xxxxxxxxxx) moči, ale xx s omezením xxxxx xx ně.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx zakázáno xxxxxxxxxxx:

1. Xxxxxxxx polymerů xxxxxxxxxx xxxxxxx nebo jejich xxxxxxx;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx případných xxxxxxxxx xxxxxxx, např. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (karfedon)/,

furfenorex,

klobenzorex,

kokain,

kropropamid,

krotetamid,

lisdexamfetamin,

mefenorex,

mefentermin,

metamfetamin (x-),

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxxx, 

x-xxxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx není xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx ne x xxxxxxxx pouze xx xx):

Xxxxxxxxx (xxxxxxxxx)****,

xxxxxxxxxxx,

xxxxxxxxxxxxxxxxx,

xxxxxxx***,

xxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxx,

xxxxx**,

xxxxxxx x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx x alfa-pyrolidinovalerofenon),

levmetamfetamin,

meklofenoxát,

metylefedrin***,

metylendioxymetamfetamin,

metylfenidát,

4-metylhexan-2-amin (xxxxxxxxxxxxxx),

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxx (xxxxxxxxxxxxx),

xxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxxx,

xxxxxxxxxxxxx*****,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx xxxxxxx a xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2017*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx a xxxxxxxx: Xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2017 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx xxx koncentraci xxxxx než 5 xxxxxxxxxx v 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. nosní, xxxx xxxxxxxx xxxx xxxx xxxxxx společně s xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, pokud xxxx xxxxxxxxxxx v xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. NARKOTIKA

Zakázané xx xxxxxxxxxxx:

Xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx(xxxxxx),

xxxxxxxx a xxxx deriváty,

hydromorfon,

metadon,

morfin,

nikomorfin,

oxykodon,

oxymorfon,

pentazocin,

petidin.

S8. KANABINOIDY

Zakázané xx xxxxxxxxxxx:

• Xxxxxxxx (např. xxxxx, xxxxxx a xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX).

• Xxxxxxxxxxxxxx, xxxx. "Xxxxx", XXX018, JWH073 x HU-210.

S9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx aplikací jsou xxxxxxxx.

XXXXX XXXXXXXX V URČITÝCH XXXXXXXX

X1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx koncentraci xxxxxxxx x xxxx 0,10 x/x.

• Xxxxxxxxxxxx xxxxx (FIA)

• Lukostřelba (XX)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. BETA-BLOKÁTORY

Beta-blokátory jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx, x kde xx to xxxxxxxx x Xxxx soutěž.

• Automobilový xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x U-rampa, x xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx potápění) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx x ploutvemi xxxx xxx xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx nebo xxx xxxxxxx, free immersion, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx na xxxx x variabilní váha.

• Střelba (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Mimo xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxx, 

xxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxxx,

xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis č. 80/2017 Xx. x. x. xxxxx xxxxxxxxx xxxx 4.1.2018.

Právní xxxxxxx x. 80/2017 Xx. x. x. byl xxxxxx právním xxxxxxxxx č. 36/2019 Sb. m. s. x xxxxxxxxx xx 26.7.2019.

Xxxxx jednotlivých xxxxxxxx xxxxx jiných xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx změna xxxxx uvedeného xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx dopingu ve xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Paříži, xxxx xxxxxxxxx v xxxxxxxxx xxxxx x x xxxxxxxxx xx xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Xxxxxx xx xxxxxxx xxxxxx xxxx vyhlášeno xxx č. 46/2008 Sb. m. s.